Company: MIRM
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001759425-25-000054
Chunk: 341

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 1
Chunk 341
---
Item 1. Financial Statements.

Mirum Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands, except share and per share data)

 September 30,2025December 31,2024 (Note 2) AssetsCurrent assets:Cash and cash equivalents$282,021 $222,503 Short-term investments93,527 57,812 Accounts receivable107,132 78,286 Inventory24,021 22,403 Prepaid expenses and other current assets23,874 11,784 Total current assets530,575 392,788 Restricted cash480 425 Long-term investments2,470 12,526 Property and equipment, net1,277 1,139 Operating lease right-of-use assets8,500 8,675 Intangible assets, net231,895 249,819 Other assets9,918 5,382 Total assets$785,115 $670,754 Liabilities and Stockholders’ EquityCurrent liabilities:Accounts payable$12,167 $14,618 Accrued expenses and other current liabilities148,192 111,933 Total current liabilities160,359 126,551 Operating lease liabilities, noncurrent7,361 7,972 Convertible notes payable, net, noncurrent309,368 308,082 Other liabilities15,981 2,509 Total liabilities493,069 445,114 Commitments and contingenciesStockholders’ equity:Preferred stock, $0.0001 par value; 10,000,000 shares authorized, and no shares issued and outstanding as of September 30, 2025 and December 31, 2024— — Common stock, $0.0001 par value; 200,000,000 shares authorized; 51,314,176 and 48,338,096 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively5 5 Additional paid-in capital953,818 870,189 Accumulated deficit(661,814)(644,181)Accumulated other comprehensive income (loss)37 (373)Total stockholders’ equity292,046 225,640 Total liabilities and stockholders’ equity$785,115 $670,754 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

1

Table